Anthropic Uses Claude to Accelerate Drug Discovery: Partners with Six Institutions and Launches Its Own Drug Discovery Program

Anthropic's life sciences team is collaborating with six institutions—BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group—to use Claude in supporting drug development, and has launched its own drug discovery program targeting diseases such as rare childhood muscular dystrophy. BMS uses Claude in clinical trial planning to analyze proprietary data, generate research plans, and assess success rates; a single prompt can accomplish preliminary analysis that would otherwise take several days. Most of the research is currently at the preclinical stage, and Anthropic plans to expand its collaboration with BMS in 2027.